Fair Value Calculator Fair Value Calculator
EN DE

Supermax Corporation (7106) Fair Value & Analysis

Healthcare · MY · Market cap 932M MYR

SC Supermax Corporation 7106 · KLSE
Price0.2600 MYR
Fair Value0.3200 MYR
Upside+23.1%
Quality34/100
Watch Supermax Corporation for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range 0.2100 MYR – 0.4000 MYR

Fair value as of: Jul 12, 2026

From 1 valuation models · updated today

Fair value updated Jul 12, 2026 — revised from 6.01 MYR to 0.3200 MYR (−94.7%) since Jun 24, 2026. Share price −13.3% over the past month.

Price vs Fair Value (12 months)

0.6400 MYR 0.2500 MYR Fair Value 0.3200 MYR Jul 2025 Jul 2026

12‑month range 0.2500 MYR – 0.6400 MYR · fair‑value band 0.2100 MYR – 0.4000 MYR · the 0.2600 MYR price screens below the 0.3200 MYR fair value. As of Jul 12, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Supermax Corporation (7106) currently trades at 0.2600 MYR, while our model-based Fair Value estimate is 0.3200 MYR — implying the stock looks roughly 23.1% undervalued today. We read business quality at 34/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

Over the trailing twelve months, Supermax Corporation generated revenue of 672M MYR at a net margin of -42.5%. Revenue declined 37.8% year over year. It earns a return on equity of -7.2%. The balance sheet holds a net cash position of 718M MYR. Fundamentals as of Jul 12, 2026

Our scenario range runs from 0.2100 MYR (bear case) to 0.4000 MYR (bull case); at 0.2600 MYR, the current price sits within that range. The share trades about 61% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -34% fair-value upside — at 23%, 7106 screens cheaper than that median.

Key figures & financial health

Revenue (TTM) 672M MYR
Revenue growth (YoY) -37.8%
Net margin -42.5%
Return on equity -7.2%
Free cash flow −360M MYR FY2024
Operating margin -32.4%
More key figures
EPS (TTM) -0.0900 MYR
EPS growth (YoY) -92.8%
Net cash 718M MYR FY2024

Figures from reported company fundamentals (EODHD) · as of Jul 12, 2026. TTM = trailing twelve months.

About the company

Supermax Corporation Berhad, an investment holding company, manufactures, distributes, and markets medical gloves and contact lenses in Europe, North America, Central America, South America, Asia, Oceania, and Africa. It operates through four segments: Investment Holding, Manufacturing of Gloves, Trading of Gloves, and Others. The company offers various types of nitrile latex and natural rubber gloves, as well as personal protective equipment. It is also involved in the trading, importing, and distribution of latex gloves; generation of biomass energy; marketing and distribution of healthcare products and medical devices; manufactures and sells face masks; and property holding activities. The company sells its products to laboratories, pharmacists, hospitals, doctors, and surgeons under the SUPERMAX, AURELIA, and MAXTER brands. It also exports its products to approximately 165 countries. The company was founded in 1987 and is headquartered in Sungai Buloh, Malaysia.

Revenue & earnings trend

FY2020 – FY2024 · reported fiscal years

Supermax Corporation reported revenue of 782M MYR in FY2024 versus 7.2B MYR in FY2020, a compound −42.5%/yr. Reported net income was −160M MYR in FY2024.

Revenue −42.5%/yr
FY20 7.2B MYR
FY21 2.7B MYR
FY22 821M MYR
FY23 646M MYR
FY24 782M MYR
Net income
FY20 3.8B MYR
FY21 719M MYR
FY22 −141M MYR
FY23 −176M MYR
FY24 −160M MYR

Is 7106 fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "Supermax Corporation Fair Value". https://www.fairvalue-calculator.com/stock/7106

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $402.95 $182.39 -55%
EssilorLuxottica Société anonyme ESLOF $190.25 $125.65 -34%
HOYA Corporation HOCPY $162.33 $101.00 -38%
Medline Inc MDLN $34.71 $30.15 -13%
Becton, Dickinson and Company BDX $147.79 $124.26 -16%
Alcon Inc ALC $65.18 $44.21 -32%
ResMed Inc R1MD34 R$253.26 R$41.40 -84%
West Pharmaceutical Services, Inc WST $330.92 $114.00 -66%
Terumo Corporation TRUMF $14.62 $12.65 -13%
Straumann Holding SAUHY $12.68 $5.49 -57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is Supermax Corporation (7106) undervalued?
As of Jul 12, 2026, our model estimates a fair value of 0.3200 MYR versus a price of 0.2600 MYR — about +23% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 7106?
Our model-based fair value for Supermax Corporation is 0.3200 MYR (as of Jul 12, 2026), built from audited fundamentals. The current price is 0.2600 MYR.
What is the quality score of 7106?
Supermax Corporation has a Quality Score of 34/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of Supermax Corporation (7106)?
Supermax Corporation reported trailing-twelve-month revenue of about 672M MYR (latest available figure, as of Jul 12, 2026).
What is the net profit margin of 7106?
The net profit margin of Supermax Corporation is about -42.5%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

14 days Pro free · no card

Unlock the full Supermax Corporation analysis — and try Pro free

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.